Radical cystectomy is the standard of care for patients with nonmetastatic high-risk bladder cancer. Robotic approach to radical cystectomy has been developed to reduce perioperative morbidities and enhance postoperative recovery while maintaining oncologic control. Classically, radical cystectomy in female patient entails anterior pelvic exenteration with removal of the bladder, uterus, fallopian tubes, ovaries, anterior vaginal wall, and urethra. Pelvic organ-sparing radical cystectomy has been adopted in carefully selected patients to optimize postoperative sexual and urinary function, especially in those undergoing orthotopic urinary diversion. In this article, we describe our techniques of both classical and organ-sparing robot-assisted laparoscopic radical cystectomy in female patients. We also review patient selection criteria, perioperative management, and alternative approaches to improve operative outcomes in female patients.
Get full access to this article
View all access options for this article.
References
1.
ChangSS, BochnerBH, ChouR, et al.Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol, 2017; 198:552–559.
2.
WitjesJA, BruinsHM, CathomasR, et al.European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol, 2021; 79:82–104.
3.
FlaigTW, SpiessPE, AgarwalN, et al.Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2020; 18:329–354.
4.
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet, 1999; 354:533–540.
5.
International Collaboration ofTrialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract CancerGroup, et al.International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol, 2011; 29:2171–2177.
6.
GrossmanHB, NataleRB, TangenCM, et al.Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003; 349:859–866.
7.
KamatAM, GeeJR, DinneyCPN, et al.The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol, 2006; 175(3 Pt 1):881–885.
8.
SylvesterRJ, van der MeijdenAPM, OosterlinckW, et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006; 49:466–5; discussion 475–7.
9.
Fernandez-GomezJ, MaderoR, SolsonaE, et al.Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guerin: The CUETO scoring model. J Urol, 2009; 182:2195–2203.
10.
Martin-DoyleW, LeowJJ, OrsolaA, ChangSL, BellmuntJ. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: A meta-analysis of 15,215 patients. J Clin Oncol, 2015; 33):643–650.
11.
ChangSS, BoorjianSA, ChouR, et al.Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol, 2016; 196:1021–1029.
12.
BabjukM, BurgerM, CompératEM, et al.European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol, 2019; 76:639–657.
13.
HerrHW, BochnerBH, DalbagniG, DonatSM, ReuterVE, BajorinDF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol, 2002; 167:1295–1298.
14.
AbdollahF, SunM, SchmitgesJ, et al.Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int, 2012; 109:1147–1154.
15.
VenkatramaniV, ReisIM, CastleEP, et al.Predictors of recurrence, and progression-free and overall survival following open versus robotic radical cystectomy: Analysis from the RAZOR trial with a 3-year followup. J Urol, 2020; 203:522–529.
16.
ParekhDJ, ReisIM, CastleEP, et al.Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): An open-label, randomised, phase 3, non-inferiority trial. Lancet, 2018; 391:2525–2536.
17.
RaiBP, BondadJ, VasdevN, et al.Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Urology Group, ed. Cochrane Database Syst Rev, 2019; 4:CD011903.
18.
WilsonTG, GuruK, RosenRC, et al.Best practices in robot-assisted radical cystectomy and urinary reconstruction: Recommendations of the Pasadena Consensus Panel. Eur Urol, 2015; 67:363–375.
19.
ChenME, PistersLL, MalpicaA, PettawayCA, DinneyCP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer: Results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J Urol, 1997; 157:2120–2123.
20.
ChangSS, ColeE, SmithJA, CooksonMS. Pathological findings of gynecologic organs obtained at female radical cystectomy. J Urol, 2002; 168:147–149.
21.
Ali-El-DeinB, Abdel-LatifM, MosbahA, et al.Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: Is it mandatory to remove these organs routinely?. J Urol, 2004; 172:885–887.
22.
DjaladatH, BruinsHM, MirandaG, CaiJ, SkinnerEC, DaneshmandS. Reproductive organ involvement in female patients undergoing radical cystectomy for urothelial bladder cancer. J Urol, 2012; 188:2134–2138.
23.
DalyMB, PilarskiR, BerryM, et al.NCCN guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J Natl Compr Canc Netw, 2017; 15:9–20.
24.
GuptaS, ProvenzaleD, LlorX, et al.NCCN guidelines insights: Genetic/familial high-risk assessment: Colorectal, version 2.2019. J Natl Compr Canc Netw, 2019; 17:1032–1041.
25.
LeeCT, ChangSS, KamatAM, et al.Alvimopan accelerates gastrointestinal recovery after radical cystectomy: A multicenter randomized placebo-controlled trial. Eur Urol, 2014; 66:265–272.
26.
LightnerDJ, WymerK, SanchezJ, KavoussiL. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol, 2020; 203:351–356.
27.
ForrestJB, ClemensJQ, FinamoreP, et al.AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol, 2009; 181:1170–1177.
28.
ChangSS, ColeE, CooksonMS, PetersonM, SmithJA. Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: Technique and results. J Urol, 2002; 168(4 Pt 1):1442–1445.
29.
KoieT, HatakeyamaS, YoneyamaT, HashimotoY, KamimuraN, OhyamaC. Uterus-, fallopian tube-, ovary-, and vagina-sparing cystectomy followed by U-shaped ileal neobladder construction for female bladder cancer patients: Oncological and functional outcomes. Urology, 2010; 75:1499–1503.
30.
Ali-El-DeinB, MosbahA, OsmanY, et al.Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: A report on 15 cases with long term follow-up. Eur J Surg Oncol, 2013; 39:358–364.
GranbergCF, BoorjianSA, CrispenPL, et al.Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int, 2008; 102:1551–1555.
ButtZM, PerlmutterAE, PiacentePM, et al.Impact of body mass index on robot-assisted radical cystectomy. JSLS, 2008; 12:241–245.
38.
AhmadiN, CliffordTG, MirandaG, et al.Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion. BJU Int, 2017; 120:689–694.
39.
BochnerBH, FigueroaAJ, SkinnerEC, et al.Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol, 1998; 160:29–33.
40.
ZlatevDV, SkinnerEC. Orthotopic urinary diversion for women. Urol Clin North Am, 2018; 45:49–54.
41.
BochnerBH, DalbagniG, MarzoukKH, et al.Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: Oncologic outcomes. Eur Urol, 2018; 74:465–471.
42.
SmithAB, CrowellK, WoodsME, et al.Functional outcomes following radical cystectomy in women with bladder cancer: A systematic review. Eur Urol Focus, 2017; 3:136–143.
43.
RosenR, BrownC, HeimanJ, et al.The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther, 2000; 26:191–208.
44.
MestonCM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther, 2003; 29:39–46.
45.
WishahiM, ElganozouryH. Survival up to 5–15 years in young women following genital sparing radical cystectomy and neobladder: Oncological outcome and quality of life. Single-surgeon and single-institution experience. Cent Eur J Urol, 2015; 68:141–145.
46.
MoursyEES, EldahshoursyMZ, GamalWM, BadawyAA. Orthotopic genital sparing radical cystectomy in pre-menopausal women with muscle-invasive bladder carcinoma: A prospective study. Indian J Urol, 2016; 32:65–70.
47.
TudertiG, MastroianniR, FlammiaS, et al.Sex-sparing robot-assisted radical cystectomy with intracorporeal padua ileal neobladder in female: Surgical technique, perioperative, oncologic and functional outcomes. J Clin Med, 2020; 9:577.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
